EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

Cost-effectiveness of hydroxychloroquine retinopathy screening: the current guideline versus no screening and reduced regimens

Sara W Quist, Sophie Te Dorsthorst, Roel D Freriks, Maarten J Postma, Carel B Hoyng, Freekje van Asten

The European Journal of Health Economics · 2025

DOI: 10.1007/s10198-024-01715-w ↗

Kurz gefasst

Leitlinie in der Zeitschrift The European Journal of Health Economics, 2025. Verfasst von Sara W Quist und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, University of Groningen, University Medical Center, Groningen, The Netherlands. s.w.quist@umcg.nl. Hauptthemen laut MEDLINE: Hydroxychloroquine, Retinal Diseases, Antirheumatic Agents, Mass Screening. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Hydroxychloroquine (HCQ) effectively treats autoimmune diseases but prolonged use may lead to retinopathy and subsequent vision loss. Guidelines suggest annual follow-up after 5 years for low-risk and 1 year for high-risk patients. This study evaluates the cost-effectiveness of current screening guidelines and a reduced regimen in the Netherlands from a societal perspective.

Methods

A Markov model assessed costs and quality-adjusted life-years (QALYs) for current and reduced screening regimens. The model included 359 HCQ-treated patients from Radboud University Medical Center. Cost-effectiveness was examined in the general population and patients using < 5.0 mg/kg, 5.0–6.0 mg/kg, or > 6.0 mg/kg HCQ per day for several reduced regimens.

Results

Compared to no screening, the current screening guideline saves costs (i.e., €210 per patient), while gaining QALYs (i.e., 0.79 QALY per patient) over a lifetime in the Netherlands. However, in patients receiving < 5.0 mg/kg HCQ per day, a biennial screening regimen after 10 years using SD-OCT was more cost-effective. For those with 5.0–6.0 mg/kg and > 6.0 mg/kg per day, initiating annual screening with an SD-OCT after 5 years was more cost-effective than the current guideline.

Conclusions

Screening for HCQ retinopathy is cost-effective, but delayed initiation and a reduced frequency, using solely an SD-OCT, are more cost-effective. We recommend screening with an SD-OCT and a biennial regimen after 10 years for low-risk patients, an annual regimen after 5 years for intermediate- and high-risk patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydroxychloroquineRetinal DiseasesAntirheumatic AgentsMass ScreeningHumansCost-Benefit AnalysisQuality-Adjusted Life YearsMarkov ChainsNetherlandsFemaleMiddle AgedMalePractice Guidelines as TopicAdultAged

Stichwörter der Autor:innen

Cost-effectivenessHydroxychloroquine retinopathyScreening guidelines

Substanzen

HydroxychloroquineAntirheumatic Agents

Autor:innen und Institutionen

  • Department of Health Sciences, University of Groningen, University Medical Center, Groningen, The Netherlands. s.w.quist@umcg.nl.
  • Asc Academics B.V., Groningen, The Netherlands. s.w.quist@umcg.nl.
  • Department of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Asc Academics B.V., Groningen, The Netherlands.
  • Department of Health Technology and Services Research, TechMed Centre, University of Twente, Enschede, The Netherlands.
  • Department of Health Sciences, University of Groningen, University Medical Center, Groningen, The Netherlands.

Zitieren

APA

Quist, S. W., Dorsthorst, S. T., Freriks, R. D., Postma, M. J., Hoyng, C. B., & van Asten, F. (2025). Cost-effectiveness of hydroxychloroquine retinopathy screening: the current guideline versus no screening and reduced regimens. The European Journal of Health Economics. https://doi.org/10.1007/s10198-024-01715-w

Vancouver

Quist SW, Dorsthorst ST, Freriks RD, Postma MJ, Hoyng CB, van Asten F. Cost-effectiveness of hydroxychloroquine retinopathy screening: the current guideline versus no screening and reduced regimens. The European Journal of Health Economics. 2025. doi:10.1007/s10198-024-01715-w

BibTeX
@article{Quist2025,
  author = {Quist, Sara W and Dorsthorst, Sophie Te and Freriks, Roel D and Postma, Maarten J and Hoyng, Carel B and van Asten, Freekje},
  title = {Cost-effectiveness of hydroxychloroquine retinopathy screening: the current guideline versus no screening and reduced regimens},
  journal = {The European Journal of Health Economics},
  year = {2025},
  doi = {10.1007/s10198-024-01715-w}
}
Kostenlos starten →